Help me understand where you are coming from. Explain how all these other drugs have EUA’s with less effect on mortality and length of stay than leronlimab? From my perspective it is because there is an uneven playing field

Quote:

---

Blood is not on the FDA's hands. CYDY's management is to blame, pure and simple. As Patterson said, "botched trial design". The FDA has the same rules they follow for every company. No one is picking on CYDY. Not a popular opinion, I know.

---